Compare · AKER vs ORKA
AKER vs ORKA
Side-by-side comparison of Akers Biosciences Inc. (AKER) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKER and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $5.82B.
- ORKA has hit the wire 2 times in the past 4 weeks while AKER has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for AKER).
- Company
- Akers Biosciences Inc.
- Oruka Therapeutics Inc.
- Price
- -
- $96.55-1.53%
- Market cap
- -
- $5.82B
- 1M return
- -
- +3.45%
- 1Y return
- -
- +609.93%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 11
Latest AKER
- SEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)
- SEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock
- SEC Form 4 filed by EAGLE CRAIG
- SEC Form 3 filed by EAGLE CRAIG
- Akers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Kaplin Adam
- SEC Form 3 filed by Kaplin Adam
- SEC Form 4: Schreiber Christopher C exercised 131,750 units of Common Stock at a strike of $0.00 and disposed of $227,798 worth of Common Stock (46,113 units at $4.94), increasing direct ownership by 3,292% to 88,238 units to cover withholding tax
- SEC Form 4 filed by Uzonwanne Jude
- SEC Form 4: Chapman Christopher C JR was granted 96,475 units of Common Stock
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)